Grifols, S.A. Sponsored ADR Class B Stock

$7.57

3.57% today

Nasdaq, Dec 27, 02:58 pm CET

ISIN

US3984384087

Symbol

GRFS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Grifols, S.A. Sponsored ADR Class B Stock price

$7.85

-15.52 66.41% 5Y

Nasdaq, Closing price Thu, Dec 26 2024

+0.03 0.38%

ISIN

US3984384087

Symbol

GRFS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$2.02b
Enterprise Value	$14.06b
P/E (TTM) P/E ratio	31.30
EV/Sales (TTM) EV/Sales	1.98
P/S ratio (TTM) P/S ratio	0.28
P/B ratio (TTM) P/B ratio	0.89
Revenue (TTM) Revenue	$7.11b
EBIT (operating result TTM) EBIT	$928.01m
Cash position	$719.79m
EPS (TTM) EPS	$0.25
P/E forward	20.26
P/S forward	0.27
EV/Sales forward	1.88
Short interest	0.40%

As a Free StocksGuide user, you can view scores for all 6,885 stocks worldwide.

Get Started for Free Today

Grifols, S.A. Sponsored ADR Class B Stock Analysis

Unlock Scores for Free

??

4 Analysts have issued a Grifols, S.A. Sponsored ADR Class B forecast:

1x Buy

25%

2x Hold

50%

1x Sell

25%

More details on Analyst Estimates Including Price Targets

4 Analysts have issued a Grifols, S.A. Sponsored ADR Class B forecast:

Buy

25%

Hold

50%

Sell

25%

Analyst Estimates with Stock Price Targets

Financial data from Grifols, S.A. Sponsored ADR Class B

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	7,106 7,106	5% 5% 100%
- Direct Costs	4,402 4,402	2% 2% 62%
Gross Profit	2,704 2,704	19% 19% 38%
- Selling and Administrative Expenses	876 876	5% 5% 12%
- Research and Development Expense	423 423	23% 23% 6%
EBITDA	1,406 1,406	28% 28% 20%
- Depreciation and Amortization	478 478	2% 2% 7%
EBIT (Operating Income) EBIT	928 928	48% 48% 13%
Net Profit	170 170	3,500% 3,500% 2%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Grifols, S.A. Sponsored ADR Class B Stock News

Neutral

Business Wire

●

17 days ago

Flat Footed Calls for Prompt Governance Overhaul at Grifols

BARCELONA, Spain--(BUSINESS WIRE)--Flat Footed LLC is the investment manager for FF Hybrid LP, Flat Footed Series LLC - Fund 3, and GP Recovery Fund LLC (collectively, with Flat Footed LLC, “Flat Footed”), holders of an aggregate 4.64% of the voting share capital of Grifols, S.A. (the “Grifols” or the “Company”). Flat Footed today sent a letter to the Grifols Board of Directors. The full text o...

Neutral

Business Wire

●

23 days ago

Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga

NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the “Board”) requesting the disclosure of important information regarding Tomas Daga, a nearly 25-year memb...

Neutral

Business Wire

●

23 days ago

Statement From Araoz y Rueda on Behalf of Certain Institutional Investors in Grifols

MADRID--(BUSINESS WIRE)--Law firm Araoz y Rueda has been independently engaged by several international and Spanish institutions (the “Clients”) holding in aggregate 5.65% of A shares and 3.88% of B shares (including ADRs) in Grifols, S.A. (“Grifols” or the “Company”). As of 29 November 2024 closing prices, the Clients' aggregate stake in Grifols is valued at €275 million. The Clients thank the...

More Grifols, S.A. Sponsored ADR Class B News

Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Head office	Spain
CEO	Nacho Abia
Employees	23,744
Founded	1940
Website	www.grifols.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now